The Efficacy of a Modified Chronomodulated Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin in Advanced Colorectal Cancer (Preliminary Data).
- Author:
Ji Young PARK
1
;
Si Young KIM
;
Jae Jin LEE
;
Hwi Joong YOON
;
Kyung Sam CHO
Author Information
1. Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea. sykim55@chollian.net
- Publication Type:Original Article
- Keywords:
Colorectal neoplasm;
Chemotherapy;
Chronotherapy;
Oxaliplatin;
5-fluorouracil;
Leucovorin
- MeSH:
Alopecia;
Anorexia;
Chronotherapy;
Colorectal Neoplasms*;
Diarrhea;
Drug Therapy;
Fluorouracil*;
Humans;
Infusions, Intravenous;
Leucovorin*;
Peripheral Nervous System Diseases;
Pruritus;
Stomatitis;
Thrombocytopenia;
Vomiting
- From:Cancer Research and Treatment
2004;36(3):199-204
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To determine the efficacy and tolerability of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in the treatment of advanced colorectal cancer. MATERIALS AND METHODS: Sixteen patients with relapsed or metastatic colorectal cancer were treated with an intravenous infusion of oxaliplatin 25 mg/m(2), 5-FU 700 mg/m(2) and leucovorin 20 mg/m(2) on days 1 to 5. The infusion of oxaliplatin was chronomodulated with a peak delivery rate at 16: 00 p.m., with 5-FU infused constantly overnight. Each course was repeated every 21 days. RESULTS: The response rate was 38.5% (95% confidence interval [CI], 13.9% to 68.4%) in the 13 measurable patients, including 1 complete response (7.7%) and 4 partial responses (30.8%). Five patients (38.5%) had a stable disease and 3 (23.0%) a progressive disease. Three patients without a measurable lesion had improved status. The median time to progression and overall survival were 29 weeks and 85 weeks, respectively. Grade 3 thrombocytopenia occurred in 2.5% (2 cycles) and grade 3 vomiting in 12.5% (2 patients). Anorexia, stomatitis, diarrhea, pruritus, alopecia and peripheral neuropathy were mild and tolerable. CONCLUSION: The modified chronomodulated infusion of oxaliplatin, 5-FU and leucovorin is effective and tolerable, but the number of patients was too small. Further study will be needed to confirm the efficacy of this regimen with a larger population of patients.
